Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22739145 | 0.84 | TOP2A (0.31) | — | |
| SCHEMBL24398909 | 0.72 | CRBN (0.36) | CRBN | |
| SCHEMBL16231564 | 0.72 | CRBN (0.33) | CRBN | |
| SCHEMBL12681266 | 0.72 | TOP2A (0.35) | CRBN | |
| SCHEMBL11198500 | 0.71 | CRBN (0.36) | CRBN | |
| SCHEMBL21101217 | 0.69 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL13069009 | 0.68 | CRBN (0.33) | CRBN | |
| SCHEMBL21101214 | 0.68 | CRBN (0.33) | CRBN | |
| SCHEMBL10155600 | 0.67 | TSHR (0.32) | — | |
| SCHEMBL5492068 | 0.67 | CRBN (0.36) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CRBN 3984/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CRBN 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.